Literature DB >> 22139200

[The other opinion: nephrotoxicity of low-dose methotrexate - a problem which does not exist].

C Fiehn1.   

Abstract

The nephrotoxicity of methotrexate (MTX) is a phenomenon which is observed in high-dose therapy for treatment of malignant diseases. Even low-dose MTX therapy for treatment of rheumatic diseases is claimed to cause impairment in renal function. The necessity to adapt the dosage of MTX therapy for renal function disorders due to other causes however has first priority. The following article describes why nephrotoxicity of low-dose MTX has no clinical relevance and why in contrast non-steroidal anti-rheumatic drugs (NSARDs) are a problematic nephrotoxic group of substances and a long-term elimination from the therapeutic armamentarium for rheumatoid arthritis (RA) should be instigated.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22139200     DOI： 10.1007/s00393-011-0909-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  8 in total

1.  Kidney biopsies in methotrexate-treated psoriatics.

Authors:  H Zachariae; H E Hansen; H Søgaard; T S Olsen
Journal:  Dermatologica       Date:  1990

Review 2.  Understanding and managing methotrexate nephrotoxicity.

Authors:  Brigitte C Widemann; Peter C Adamson
Journal:  Oncologist       Date:  2006-06

Review 3.  Methotrexate transport mechanisms: the basis for targeted drug delivery and ß-folate-receptor-specific treatment.

Authors:  C Fiehn
Journal:  Clin Exp Rheumatol       Date:  2010-10-28       Impact factor: 4.473

Review 4.  [Is methotrexate nephrotoxic? Dose-dependency, comorbidities and comedication].

Authors:  U Erdbrügger; K de Groot
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

5.  [Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters].

Authors:  G Westhoff; C Weber; A Zink
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

6.  Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis.

Authors:  P Seideman; R Müller-Suur
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

7.  Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy.

Authors:  J M Kremer; G F Petrillo; R A Hamilton
Journal:  J Rheumatol       Date:  1995-01       Impact factor: 4.666

8.  Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months.

Authors:  J M Kremer; G F Petrillo; R A Hamilton
Journal:  J Rheumatol       Date:  1995-01       Impact factor: 4.666
  8 in total
  2 in total

Review 1.  [Characteristics of pharmacotherapy in older patients with rheumatism].

Authors:  H-J Lakomek; Christian Schulz
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

2.  What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?

Authors:  Georgina Nakafero; Matthew J Grainge; Tim Card; Christian D Mallen; Weiya Zhang; Michael Doherty; Maarten W Taal; Guruprasad P Aithal; Abhishek Abhishek
Journal:  Rheumatology (Oxford)       Date:  2021-12-01       Impact factor: 7.580
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.